Q10 and Kisqali drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Q10 (coenzyme q - 10) and Kisqali (ribociclib succinate). Common drug interactions include neutropenia among females.

The phase IV clinical study analyzes what interactions people have when they take Q10 and Kisqali. It is created by eHealthMe based on reports of 14 people who take the same drugs from the FDA, and is updated regularly.

What is Q10?

Q10 has active ingredients of coenzyme q - 10. eHealthMe is studying from 34,261 Q10 users. Check the latest studies of Q10.

What is Kisqali?

Kisqali has active ingredients of ribociclib succinate. eHealthMe is studying from 25,050 Kisqali users. Check the latest studies of Kisqali.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 28, 2026

14 people who take Q10 and Kisqali together, and have interactions are studied.

What are the common drug interactions of Q10 and Kisqali, by gender? *:

female:

Neutropenia (an abnormally low number of neutrophils)
Headache (pain in head)
Neutrophil count decreased (less than normal number of neutrophil a type of blood cell)
Neutrophil percentage decreased
Platelet count decreased
Red blood cell count decreased
Red cell distribution width increased
White blood cell count decreased
Pneumonitis (inflammation of the walls of the alveoli in the lungs)
Amnesia (deficit in memory caused by brain damage, disease, or psychological trauma)

male:

n/a

What are the common drug interactions of Q10 and Kisqali, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

Basophil percentage increased
Eosinophil percentage decreased
Haematocrit decreased
Haemoglobin decreased
Headache (pain in head)
Hot flush (sudden feelings of heat)
Lymphocyte percentage increased
Mean platelet volume increased (more than normal average size of platelet cells in blood)
Monocyte percentage increased
Neutropenia (an abnormally low number of neutrophils)

40-49:

n/a

50-59:

Electrocardiogram qt prolonged

60+:

Neutropenia (an abnormally low number of neutrophils)
Pneumonitis (inflammation of the walls of the alveoli in the lungs)
Hypoaesthesia (reduced sense of touch or sensation)
Limb discomfort (discomfort in leg)
Muscular weakness (muscle weakness)
Nervousness
Palpitations (feelings or sensations that your heart is pounding or racing)
Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect)
Rash
Rash generalised (rash on most of body parts)

What are the existing conditions these people have? *

Breast Cancer Female: 5 people, 35.71%
Breast Cancer: 4 people, 28.57%
Breast Cancer Metastatic: 2 people, 14.29%
Pain: 1 person, 7.14%
Ovarian Disorder (disease of ovary): 1 person, 7.14%
Metastasis (spreadable cancer to other organ from origin): 1 person, 7.14%
Indigestion: 1 person, 7.14%
Arthritis (form of joint disorder that involves inflammation of one or more joints): 1 person, 7.14%

* Approximation only. Some reports may have incomplete information.

Do you take Q10 and Kisqali?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously